Press Releases

INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022

Posted on April 26, 2022

INOVIO to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Posted on March 8, 2022

INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results

Posted on March 1, 2022

INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

Posted on February 15, 2022

INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

Posted on December 14, 2021

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

Posted on November 30, 2021

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

Posted on November 16, 2021

INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

Posted on November 15, 2021

INOVIO Reports Third Quarter 2021 Financial Results

Posted on November 9, 2021

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

Posted on November 9, 2021

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.